A Phase 1/2 Dose Escalation and Randomized Expansion Study of Safety, Tolerability, and Pharmacokinetics of MT-125 Monotherapy With Chemoradiation in Patients With Newly Diagnosed MGMT Methylated Glioblastoma

This study is testing an investigational medication called MT-125 alongside standard radiation and chemotherapy for people newly diagnosed with a specific type of aggressive brain tumor called glioblastoma. Researchers want to find the safest and most effective dose of this new medicine to help improve future treatments.

You might be able to join if you are 18 or older, have been newly diagnosed with this specific brain tumor, and are generally well enough to go about your daily activities. Pregnant or breastfeeding individuals, or those with other serious health conditions, will not be able to participate.

During the study, you will receive the MT-125 medication five days a week along with your standard outpatient radiation and chemotherapy for six weeks. Doctors will closely monitor your health and safety throughout the process to see how your body handles the treatment.

The study will take place at medical centers in Phoenix, Arizona; Jacksonville, Florida; and Rochester, Minnesota. It is not yet open for enrollment, but planning is underway to start soon.